CJC-1295 (Modified GRF 1-29)
CJC-1295 is a synthetic analog of growth hormone releasing hormone with amino acid substitutions that markedally extend its half-life compared to natural GHRH. It comes in two forms: with DAC (Drug Affinity Complex) which binds to albumin for a half-life of about 8 days, and without DAC (also called Modified GRF 1-29) which has a half-life of about 30 minutes. The no-DAC version is preferred in most clinical protocols because it produces more natural, pulsatile GH release.
FormBlends Peptide Context
Reviewed May 14, 2026The strongest way to read Cjc 1295 peptide guide is to look for what changes the next step. For peptide therapy, that means checking whether the page is explaining evidence, eligibility, cost, safety, provider fit, or day-to-day use. The goal is not more words on the page. It is a clearer path from a broad question to a responsible medical conversation.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Clinical decision snapshot
CJC-1295 authority snapshot
CJC-1295 is evaluated by mechanism, evidence quality, regulatory status, practical access, and safety questions a licensed clinician would need to review before use.
Evidence signal
Meaningful evidence with limits
Regulatory reality
Reinstated for compounding (Feb 2026)
Safety screen
Flushing and warmth after injection, Water retention, Headache should be reviewed in context.
This page currently connects to 5 source-backed evidence items through visible references or structured citation data.
Decision path
What is the supervised-review path for CJC-1295?
CJC-1295 should be evaluated by evidence quality, safety status, source quality, dosing context, and whether the goal fits a legitimate clinical pathway. This page is a research and decision aid, not a self-prescribing guide.
- Peptide
- CJC-1295
- Category
- Growth Hormone
- Evidence
- Meaningful evidence with limits
- FDA status
- Not FDA approved
Step 1
Check evidence level
CJC-1295 has human pharmacokinetic data showing sustained GH elevation over days (with DAC modification) or hours (without DAC). A Phase 1/2 study confirmed dose-dependent GH and IGF-1 increases in healthy adults. The evidence is moderate because the trials are small and focused on pharmacokinetics rather than clinical outcomes.
Review evidenceStep 2
Screen safety context
Flushing and warmth after injection, Water retention, Headache should be discussed in light of history, dose, and source.
Check side effectsStep 3
Confirm access route
If FormBlends offers access, review the product page and provider pathway before deciding.
Review product accessGrowth hormone axis hub
CJC-1295 and ipamorelin pages should explain the GH-axis decision
CJC-1295 and ipamorelin are not best handled as generic performance peptides. The useful read is whether the goal involves sleep, body composition, recovery, or growth hormone signaling, and whether labs, contraindications, and expectations make the pathway reasonable.
Decision question for CJC-1295
Is the reader trying to optimize recovery, or are there symptoms that need endocrine evaluation first?
Peptide evidence layer
Evidence read
The strongest content should explain GHRH analog signaling, ghrelin receptor activity, IGF-1 context, why pulses matter, and why outcomes are not the same as direct growth hormone treatment.
Safety watch
A careful screen should consider diabetes risk, edema, carpal tunnel symptoms, cancer history, sleep apnea, headaches, elevated IGF-1, and whether symptoms point to another endocrine condition.
Conversion fit
The conversion path should route to provider review with lab context, sleep history, body-composition goals, and medication history instead of promising fast performance outcomes.
Last updated: April 3, 2026
Typical Dosage
CJC-1295 no DAC: 100-300 mcg per injection, 1-3 times daily. CJC-1295 with DAC: 1000-2000 mcg once or twice per week.
Administration
Subcutaneous injection
Typical Cost
$150-300/month
FDA Status
Not FDA Approved
Half-Life
CJC-1295 with DAC: 5-8 days. CJC-1295 without DAC (mod GRF 1-29): 30 minutes.
Onset of Action
With DAC: GH elevation begins within hours and persists for days. Without DAC: GH pulse within 15-30 minutes, lasting 2-3 hours.
Bioavailability
Subcutaneous injection. Not orally bioavailable.
About CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with 30 amino acids. Two versions exist: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (also called modified GRF 1-29 or mod GRF). The DAC modification clearally extends the half-life.
The original CJC-1295 with DAC was developed by ConjuChem Biotechnologies. A 2006 study in the Journal of Clinical Endocrinology and Metabolism (PMID: 16352683) showed that a single subcutaneous injection produced GH elevation lasting over 6 days and IGF-1 elevation lasting 9-11 days in healthy adults. That's notable for a peptide, and it's entirely due to the DAC modification, which allows CJC-1295 to bind to albumin in the bloodstream and avoid rapid degradation.
CJC-1295 without DAC (mod GRF 1-29) has a much shorter half-life of about 30 minutes. It produces a sharp GH pulse that better mimics natural pulsatile GH release. Many practitioners prefer this version because the sustained GH elevation from CJC-1295 DAC can blunt the natural GH rhythm, and some patients report water retention and numbness with the longer-acting version.
The most common protocol for CJC-1295 without DAC is 100-200 mcg injected subcutaneously 2-3 times daily, usually combined with ipamorelin (200-300 mcg) at the same time. The combination targets two different receptor pathways (GHRH receptor and ghrelin receptor), producing a synergistic GH pulse stronger than either compound alone.
For CJC-1295 with DAC, the typical protocol is 2 mg injected subcutaneously once or twice per week. The extended half-life means less frequent dosing, but it also means the body is exposed to continuously elevated GH signaling, which isn't how natural GH secretion works.
Both versions were restricted from US compounding in 2023 and reinstated in February 2026. They remain widely used in anti-aging and sports medicine practices.
Store lyophilized CJC-1295 (either version) at -20C. Reconstitute with bacteriostatic water, swirling gently. Store reconstituted vials at 2-8C. Use CJC-1295 without DAC within 21 days of reconstitution. CJC-1295 with DAC is slightly more stable and can be used within 28 days.
How CJC-1295 Works
CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, stimulating growth hormone synthesis and secretion. The four amino acid substitutions at positions 2, 8, 15, and 27 protect it from enzymatic breakdown by dipeptidyl peptidase-IV (DPP-IV). The DAC version creates continuously elevated GH levels, while the no-DAC version allows for more physiologic pulsatile release when combined with a secretagogue like ipamorelin.
Receptor targets:
Benefits
- Sustained elevation of growth hormone and IGF-1 levels
- Supports muscle growth and fat metabolism
- Improves sleep quality when dosed at bedtime
- Enhances recovery from exercise and injury
- Promotes collagen synthesis and joint health
- Increases bone mineral density over time
- Synergizes strongly with GH secretagogues for amplified effect
What Does the Research Say?
CJC-1295 has human pharmacokinetic data showing sustained GH elevation over days (with DAC modification) or hours (without DAC). A Phase 1/2 study confirmed dose-dependent GH and IGF-1 increases in healthy adults. The evidence is moderate because the trials are small and focused on pharmacokinetics rather than clinical outcomes.
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth-hormone-releasing hormone
Journal of Clinical Endocrinology and Metabolism, 2006 · DOI · PubMed
Single subcutaneous dose of CJC-1295 DAC produced sustained GH elevation for 6+ days and IGF-1 elevation for 9-11 days in healthy adults
Pharmacokinetics and pharmacodynamics of growth hormone-releasing factor analog CJC-1295
Drug Metabolism and Disposition, 2008 · PubMed
Confirmed dose-dependent and sustained GH/IGF-1 elevation with CJC-1295 DAC across multiple dose levels in human subjects
PubMed evidence trail
Research sources used to frame this page
For CJC-1295, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Potential Side Effects
- Flushing and warmth after injection
- Water retention
- Headache
- Joint stiffness at higher doses
- Tingling in hands and feet
Drug Interactions
| Compound | Interaction | Severity |
|---|---|---|
| Somatostatin analogs | Somatostatin directly counteracts GHRH signaling. These work in opposite directions and should not be combined. | major |
Who Is CJC-1295 For?
Women
No sex-specific contraindications. Limited sex-specific data. The pharmacokinetic studies included both men and women.
Adults Over 50
Relevant for age-related GH decline. The extended half-life of CJC-1295 DAC means less frequent dosing, which can improve adherence in older patients.
Athletes
Banned by WADA under growth hormone releasing factors (S2). Commonly used in bodybuilding, often combined with ipamorelin.
Regulatory Status
FDA Approved
No
Compounding Legal
Yes
2026 HHS Status
Reinstated for compounding (Feb 2026)
CJC-1295 (both with and without DAC) was reinstated for compounding in February 2026 after being restricted in the 2023 FDA peptide actions.
Last verified: 2026-04-06
Stacking Options
CJC-1295 is commonly stacked with the following peptides for enhanced results:
Conditions Addressed
Get CJC-1295 from FormBlends
Pharmaceutical-grade cjc-1295 with free physician consultation.
View Product DetailsFind a CJC-1295 Clinic Near You
Browse peptide therapy clinics in your area that offer cjc-1295 treatments.
Find Peptide Clinics